WealthHorizon Life
Product Detail
- Single Premium Index-Linked Life Insurance
- Issue Ages: 45-80 (based on insured’s last birthday)
- Premium Minimum: $10,000, Maximum: $750,000 Face
- Accounts: 1 fixed-rate, 2 S&P 500 Index, 1 Barclays Focus50 Index, 1 S&P MARC 5 Excess Returns Index
- Surrender Charge: 10 years
- 12, 12, 12, 12, 11, 10, 8, 6, 4, 2%
- Upon full surrender, unearned monthly deduction will be refunded
- Face Amount: Single premium multiplied by the face amount factor
- Death Benefit: The greater of (1) Face Amount, less Loan Balance or (2) Maximum of Accumulation Value or Minimum Guaranteed Cash Value, multiplied by the minimum death benefit factor, less Loan Balance.
- Underwriting: Point of Sale up to $250,000 in premium. Cases $250,000 and above in premium require an Attending Physicians Statement (APS).
- Penalty-Free Withdrawals: 5% of Accumulation Value after 1st year, limited to one withdrawal per policy year.
- Loans: Current rate is 5.50%, variable rate
- Policy Fees/Expenses
- Policy Expense Charge: per $1,000 – years 1-10
- Policy Fee: $10 per month
- COI Charge: monthly, from Accumulation Value
- Guaranteed COIs are based on 2017 CSO Table
- Accelerated Death Benefit Rider
- Terminal Illness, Nursing Care Confinement or Chronic Care
For Agent Use Only
Product Features and Rider Availability may vary by state.
WealthHorizon Life
Current Rate | |
---|---|
1-Year Interest | 4.00% |
S&P 500 1-Year Point-to-Point Cap | 9.00% |
S&P 500 1-Year Monthly Average Participation | 75.00% |
Focus50 1-Year Point-to-Point Participation | 140.00% |
MARC 5% 1-Year Point-to-Point Participation | 150.00% |
1-Year Interest |
S&P 500 1-Year Point-to-Point Cap |
S&P 500 1-Year Monthly Average Participation |
Focus50 1-Year Point-to-Point Participation |
MARC 5% 1-Year Point-to-Point Participation |
Product State Approvals
Product State Variations
Product Not Approved |
MT, NY |
Waiver of Surrender Charge Rider Available |
FL* (Nursing Home confinement only) |
Current Form Date | Title | Number |
---|---|---|
2020/06/03 | Agent Gateway Website | ET-GATEWAY |
2020/03/31 | Barclays Focus50 Index Client Brochure | ET-BARCFOC50-1100 |
2010/05/10 | Buyer's Guide to Life Insurance - Generic | LIG-LN-06 |
2018/06/06 | E-Applications Flyer | ET-EAPP |
2020/03/24 | EquiTrust Corporate Brochure | ET-BRO-1000 |
2020/03/24 | EquiTrust Letter of Financial Condition - Producer Use Only | ET-LFC |
2009/11/01 | EquiTrust Pocket Folder | ET-FDR-1001A |
2021/01/27 | EquiTrust Wire-Transfer Instructions | ET-WIRETRANSFER |
2020/10/09 | EquiTrust's Competitive Advantages | ET-ADVANTAGES |
2019/07/30 | Extreme Impairments List | ETL-SPL-EXIMP |
2020/03/18 | Guidelines to Assure Smooth Processing of Your Life Cases | ETL-UNDTIPS |
2019/07/14 | Index-Strategy Description: 1-Year Monthly Average Participation | ETL-AP |
2017/02/14 | Index-Strategy Description: 1-Year Monthly Cap | ETL-MC |
2019/07/26 | Index-Strategy Description: 1-Year Point-to-Point Cap | ETL-PTP |
2019/07/26 | Index-Strategy Description: 1-Year Point-to-Point Participation | ETL-PTPP |
2020/03/25 | Life Underwriting Guidelines | ETL-SPL-UNDGDLNS |
2020/03/02 | Online Marketing Resources | ET-5002 |
2019/10/30 | Pre-Qualification Health Checklist | ETL-PREQUAL |
2020/03/31 | S&P MARC 5% Excess Return Client Brochure | SPMARC5BROCHURE |
2021/01/05 | S&P500 Historical Analysis | ET-SP500-HISTORICAL |
2020/07/09 | Ward's 50 | ET-WARDS50 |
2020/05/27 | Wealth Series Sales Presentation - PowerPoint | ETL-BRO-1009PP |
2019/07/30 | Wealth Series Sales Presentation | ETL-BRO-1009 |
2019/07/30 | WealthHorizon Life Agent Guide - CA | ETL-WHRZN-1102CA |
2019/07/30 | WealthHorizon Life Agent Guide - Generic | ETL-WHRZN-1102 |
2019/07/30 | WealthHorizon Life Case Study Flyer | ETL-WHRZN-CASE |
2019/08/08 | WealthHorizon Life Case Study Flyer - Age 60 | ETL-WHRZN-CASE60 |
2019/07/30 | WealthHorizon Life Client Brochure - CA | ETL-WHRZN-1100CA |
2019/07/30 | WealthHorizon Life Client Brochure - Generic | ETL-WHRZN-1100 |
2019/07/30 | WealthHorizon Life Face Amount Factors | ETL-WHRZNFAF |